Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › solanezumab

solanezumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of solanezumab

2 trials tracked of solanezumab: 2 in phase 3 or 4 and 2 with published results. The most-cited published study has 37 citations.

2Trials tracked
2Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 3 2
  1. Phase 3 Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Completed · 37 cited
  2. Phase 3 Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss Completed · 11 cited

Showing the 2 most-cited and recently-updated of 2 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
APOE ε4 carrier status does not accelerate cognitive decline in mild-to-moderate Alzheimer's disease
Neurology Phase III
APOE ε4 carrier status does not accelerate cognitive decline in mild-to-moderate Alzheimer's disease Genetic markers may relate to Alzheimer's severity but not speed
This observational analysis of the EXPEDITION 1 placebo arm involved 343 patients with mild-to-moderate Alzheimer's disease. The study found…
A new look at Alzheimer's data shows that a specific gene might affect how severe the disease is at first.
medRxiv Sep 30, 2026
Meta-analysis finds trivial cognitive effects of amyloid antibodies in mild Alzheimer's disease
Neurology Meta-analysis
Meta-analysis finds trivial cognitive effects of amyloid antibodies in mild Alzheimer's disease Alzheimer’s Drugs Clear Plaques But Don’t Help Memory
This meta-analysis of 17 randomized trials found amyloid-beta-targeting monoclonal antibodies probably have little to no effect on cognitive…
This review shows that even when Alzheimer’s drugs clear amyloid from the brain, patients don’t see meaningful improvements in memory or dai…
Apr 22, 2026